Sonnet BioTherapeutics Holdings Inc. is an oncology-focused biotechnology company with a proprietary platform for biologic drugs of single or bispecific action. Sonnet BioTherapeutics Holdings Inc., formerly known as Chanticleer Holdings Inc., is based in PRINCETON, N.J.
| Revenue (Most Recent Fiscal Year) | $0.02M |
| Net Income (Most Recent Fiscal Year) | $-7.44M |
| PE Ratio (Current Year Earnings Estimate) | -- |
| PE Ratio (Trailing 12 Months) | -- |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | -- |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | -- |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | -- |
| Pre-Tax Margin (Trailing 12 Months) | -1339.60% |
| Net Margin (Trailing 12 Months) | -- |
| Return on Equity (Trailing 12 Months) | -4646.10% |
| Return on Assets (Trailing 12 Months) | -342.21% |
| Current Ratio (Most Recent Fiscal Quarter) | 0.26 |
| Quick Ratio (Most Recent Fiscal Quarter) | 0.26 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | 0.00 |
| Inventory Turnover (Trailing 12 Months) | -- |
| Book Value per Share (Most Recent Fiscal Quarter) | $-0.71 |
| Earnings per Share (Most Recent Fiscal Quarter) | $-0.95 |
| Earnings per Share (Most Recent Fiscal Year) | $-11.35 |
| Diluted Earnings per Share (Trailing 12 Months) | -- |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Common Shares Outstanding | 6.83M |
| Free Float | 6.25M |
| Market Capitalization | $48.20M |
| Average Volume (Last 20 Days) | 1.32M |
| Beta (Past 60 Months) | 1.21 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 8.48% |
| Percentage Held By Institutions (Latest 13F Reports) | 9.45% |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |